KR20090018930A - Cgrp-수용체 길항제로서의 구속 화합물 - Google Patents

Cgrp-수용체 길항제로서의 구속 화합물 Download PDF

Info

Publication number
KR20090018930A
KR20090018930A KR1020087029499A KR20087029499A KR20090018930A KR 20090018930 A KR20090018930 A KR 20090018930A KR 1020087029499 A KR1020087029499 A KR 1020087029499A KR 20087029499 A KR20087029499 A KR 20087029499A KR 20090018930 A KR20090018930 A KR 20090018930A
Authority
KR
South Korea
Prior art keywords
oxo
mmol
mixture
chloro
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087029499A
Other languages
English (en)
Korean (ko)
Inventor
프라사드 브이. 차투르베둘라
스티븐 이. 메르세르
하이취엔 팡
샤오준 한
광린 루오
진 엠. 듀바우칙
그라함 에스. 포인덱스터
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20090018930A publication Critical patent/KR20090018930A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020087029499A 2006-05-03 2007-05-02 Cgrp-수용체 길항제로서의 구속 화합물 Withdrawn KR20090018930A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79740006P 2006-05-03 2006-05-03
US60/797,400 2006-05-03
US11/742,626 2007-05-01
US11/742,626 US7470680B2 (en) 2006-05-03 2007-05-01 Constrained compounds as CGRP-receptor antagonists

Publications (1)

Publication Number Publication Date
KR20090018930A true KR20090018930A (ko) 2009-02-24

Family

ID=38544174

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087029499A Withdrawn KR20090018930A (ko) 2006-05-03 2007-05-02 Cgrp-수용체 길항제로서의 구속 화합물

Country Status (14)

Country Link
US (1) US7470680B2 (cg-RX-API-DMAC7.html)
EP (1) EP2013214B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009535429A (cg-RX-API-DMAC7.html)
KR (1) KR20090018930A (cg-RX-API-DMAC7.html)
AR (1) AR060845A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007248038A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0709759A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651033A1 (cg-RX-API-DMAC7.html)
IL (1) IL195027A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008013760A (cg-RX-API-DMAC7.html)
NO (1) NO20084564L (cg-RX-API-DMAC7.html)
PE (1) PE20080232A1 (cg-RX-API-DMAC7.html)
TW (1) TW200813063A (cg-RX-API-DMAC7.html)
WO (1) WO2007131020A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
CA2672230A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンcgrp受容体アンタゴニスト
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2024220626A1 (en) * 2023-04-20 2024-10-24 Azkarra Therapeutics, Inc. Small molecule modulators of ogg1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606286B1 (en) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
WO2004091514A2 (en) 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1641781B1 (en) * 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
US7476665B2 (en) * 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
CN101124217A (zh) 2004-01-29 2008-02-13 默克公司 Cgrp受体拮抗剂
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US7659264B2 (en) 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
DE602005027870D1 (de) 2004-10-14 2011-06-16 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP1856100B1 (en) 2005-01-18 2010-05-05 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
EP1861399B1 (en) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CA2615463A1 (en) 2005-07-29 2007-02-08 Merck & Co., Inc. Heterocyclic benzodiazepine cgrp receptor antagonists
CA2672230A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists

Also Published As

Publication number Publication date
TW200813063A (en) 2008-03-16
PE20080232A1 (es) 2008-04-11
WO2007131020A3 (en) 2008-01-17
CA2651033A1 (en) 2007-11-15
US7470680B2 (en) 2008-12-30
JP2009535429A (ja) 2009-10-01
NO20084564L (no) 2008-12-02
US20070259851A1 (en) 2007-11-08
WO2007131020A2 (en) 2007-11-15
BRPI0709759A2 (pt) 2011-10-25
AR060845A1 (es) 2008-07-16
IL195027A0 (en) 2009-08-03
EP2013214B1 (en) 2015-06-24
MX2008013760A (es) 2008-11-14
EP2013214A2 (en) 2009-01-14
AU2007248038A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
US7544680B2 (en) Constrained compounds as CGRP-receptor antagonists
JP5116687B2 (ja) がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
IL282622A (en) Substituted tricyclic compounds as fgfr inhibitors
EP3480198B1 (en) Novel compound or pharmaceutically acceptable salt thereof
WO2007130860A2 (en) Constrained compounds as cgrp-receptor antagonists
KR20160002812A (ko) 단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물
EP2013214B1 (en) Constrained compounds as cgrp-receptor antagonists
WO2016134314A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
EP2013213B1 (en) Constrained compounds as cgrp-receptor antagonists
TW202317561A (zh) 作為治療劑的具有1h—吡唑并[4,3—c]吡啶—6—胺基的化合物
CN101495480B (zh) 作为降钙素基因相关肽受体拮抗剂的受限化合物
US20090054440A1 (en) Quinoline derivatives as neurokinin receptor antagonists
CN101094854A (zh) 作为cgrp受体拮抗剂的受限化合物
CN121949345A (zh) 杂芳基大环化合物及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid